Zim Laboratories Ltd
NSE:ZIMLAB
Zim Laboratories Ltd
Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Revenue Growth: Zim Laboratories reported Q3 operating income of INR 1,087 million, with improvement both sequentially and year-over-year, driven by strong pharma and recovering nutraceuticals segments.
Profitability: EBITDA for the quarter was INR 145 million (margin of 13.4%), and profit after tax was INR 44 million, both improving from the previous quarter.
Export Boost: Export business surged 23.2% YoY in Q3 to INR 961 million, contributing 88% of total operating income.
EU-GMP Remediation: The company has addressed most CAPA points and expects an EU-GMP audit in Q1 FY '27 (likely April–June), which is seen as crucial to unlocking regulated market sales.
Preferential Issue: Raised INR 35 crores via a preferential issue to support nutraceutical facility expansion and CAPA-related compliance; about 10% of proceeds allocated for CAPA.
Product Expansion: NIP and OTF products contributed INR 132 million (12.2% of operating income); launches in regulated markets expected post-EU-GMP clearance.
Leadership Strengthening: Key senior hires made to enhance international business, quality assurance, and HR, supporting growth strategy.
Guidance & Outlook: Management expects Q4 to be in line with Q3 and sees significant uptick in the last quarter post-EU-GMP remediation, especially in regulated markets.
